Biosimilars in the European market
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
Introduction and study objectives: To describe the development of biosimilars in 24 European Union (EU) Member States, plus Norway and Switzerland, and to identify the key parameters associated with biosimilars market dynamics across EU Member States. Methods: A quantitative analysis of the EU biosimilar market from 2007 to 2010 was conducted. Data were obtained from the European Medicines Agency (EMA) and the IMS MIDAS database, which include for each EU Member States: date of market entry of all biosimilars authorized by EMA up to 31 December 2010 and their respective reference products, unit sales, prices and market value of existing biosimilars and their respective reference products. The variables used to characterize market dynamics were: 1) time period between EMA’s approval and market entry; 2) market share; 3) market exclusivity period. The analysis also explores whether country differences in the former variables are associated with characteristics such as pharmaceutical policies applied, demographics and economic factors. Results: The market share of biosimilars for the three reference molecules (somatropin, epoietin and filgrastim) rose from 0.33% (2007) to 15.52% (2010). Faster biosimilar launches were explained by generics price control policy, countries’ gross national income and expenditure on health, pharmacists’ generics substitution and medicines’ price level index. Conclusion: Biosimilars may help lower the cost of biological medicines. Existing EU evidence is still limited and results show no clear pattern of market dynamics, although it is likely that biosimilars will result in smaller price reductions and lower market share than conventional generics.
Authors and Affiliations
Joan Rovira, Leandro Lindner, Emmanuel Giménez, Jaime Espín, Antonio Olry de Labry, Leticia García
Keywords
Related Articles
- EP ID EP355097
- DOI 10.5639/gabij.2013.0201.012
- Views 112
- Downloads 0
Update on clinical practice guideline on the use of epoetin and darbepoetin in adult patients with cancer
Chemotherapy-induced anaemia can be treated using erythropoiesis-stimulating agents (ESAs), but these can cause serious side-effects including tumour progression, venous thromboembolism, and shorter survival. Following e...
Innovator companies should focus on innovations
Despite biopharmaceuticals having an enormous potential value for our health, they have also become a serious threat to our healthcare systems.
The potential of generics policies: more room for exploitation–PPRI Conference Report
Introduction: This Conference Report aims to provide an overview of key results, messages and conclusions of the Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference with regard to generics. Methods: Th...
Terminology for biosimilars–a confusing minefield
Biosimilars are firmly established in the EU as copy biologicals with a clear and effective regulatory route for approval. Unfortunately, inconsistency in nomenclature for biosimilars has caused confusion. This problem o...
Biosimilarity of anticancer monoclonal antibodies in the clinic
The European Medicines Agency recommends the use of pharmacodynamics (PD) markers when establishing biosimilarity, but no such biomarkers are known for the clinical efficacy of bevacizumab (Avastin). For this reason, con...